IBJNews

Lilly finds solace in new Alzheimer's study

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.

Indianapolis-based Lilly announced on Dec. 12 that it will conduct another Phase 3 trial of the drug solanezumab to show that the drug slows the progression of Alzheimer’s disease. In October, scientists detailed clinical trial results that showed the drug moderately slowed the decline in mental abilities in patients with mild forms of the memory-sapping disease.

But a week before that announcement, the journal Neuron published a paper by a team of 13 Alzheimer’s researchers at Lilly, which they think proves the science behind solanezumab is sound.

That could be significant because Lilly, which is losing patent protection on its older neuroscience blockbusters Zyprexa and Cymbalta, has staked enormous resources on bringing an Alzheimer’s drug to market. If successful, it could reap billions of dollars per year in sales.

“We learned a lot from solanezumab and that was the key point for how we figured out how to attack this,” said Ron DeMattos, Lilly’s lead biologist on solanezumab and the lead author of the new study.

The Neuron study tested a new drug’s ability to reduce the buildup of plaques in the brain that are a key marker of Alzheimer’s disease and, according to some theories, the cause of its damage.

These plaques are formed by the clumping and tangling of chunks of a brain protein called amyloid-beta. It is produced in every person’s brain but reaches excess levels in the brains of Alzheimer’s patients.

Removing amyloid or slowing its production are the goals of nearly all the experimental Alzheimer’s drugs being tested now by major pharmaceutical companies. Alzheimer’s disease is getting such attention because there is no effective treatment for it currently and the costs of caring for Alzheimer’s patients are estimated to be $180 billion per year in the United States alone.

Lilly’s scientists designed solanezumab to attach to free-floating pieces of amyloid and carry them out of the brain tissue into the spinal fluid or the bloodstream.

Solanezumab does not attach to amyloid plaques. But Lilly’s scientists reasoned that, as solanezumab reduced the levels of free-floating amyloid that hover around the amyloid plaques like a cloud, more of the amyloid pieces clumped up in plaques would be able to jump off and float away.

In its latest study, Lilly scientists designed a new drug, called mE8, that attaches only to amyloid plaques, but not to the free-floating pieces of amyloid surrounding the plaques.

Lilly’s drug, which is known as mE8, showed a better ability to remove plaque than the mouse version of a competing drug called bapineuzumab. That drug, which was developed by Ireland-based Elan Corp. and tested by New York-based Pfizer Inc. and New Jersey-based Johnson & Johnson, failed in a Phase 3 clinical trial this summer. Human studies of the drug were discontinued.

DeMattos attributed the differences to the fact that bapineuzumab attaches to both free-floating amyloid and to amyloid plaques. Much of the drug appears to have become clustered with free-floating amyloid before it could ever reach amyloid plaques in most parts of the brain.

He also noted that Lilly’s drug mE8 showed no bleeding in the brain, called microhemorrhaging. The mouse version of bapineuzumab did show some bleeding in mice brains.

“We’re really enthusiastic about this approach,” DeMattos said, noting that a humanized version of mE8 drug would be the next Alzheimer’s drug Lilly moves into clinical trials. In addition to solanezumab, Lilly already has one other drug in human trials.

DeMattos said it is likely that Alzheimer’s will be successfully treated through a combination of drugs, rather than just one. However, he said Lilly would need to thoroughly study both solanezumab and mE8 separately before it considers whether they could be used as a combination therapy.

“This has become a very hot topic among the academic clinicians,” DeMattos said of a combination therapy. “Lilly is uniquely positioned in that we have an antibody that targets the soluble [amyloid] beta and we have an antibody that targets the plaques specifically.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Uh, sorry Johnnie, but you are incorrect. Despite the assertions by yourself and various defenders and captains, sports attendance is NOT off significantly at most sporting events in the US. Variances in attendance has been in the range of single digits, both + & - for years now. MLB has had most of its best overall attendance nubers in the last decade, and that trend has been consistent for most major sporting events. The number one issue cited by most fans when asked about attendance is the overall cost of attending. The presence of HD and big screen televisions in home doesn't even register, as a factor for not attending an event. VALUE in the product is the key, and apparently is something lacking in the current ICS. What other explanation is there when with what is routinely touted as the "best" racing on the planet, fans are staying away in DROVES. A "close" title battle into the last event at Fontana, with the "cars and stars" of the ICS, and who showed up? MAYBE 8K. Sorry, but HD TV isn't to blame for that kind of fan apathy.

  2. Do you need finance to establish your business ? Are you interested in getting a loan at 3% from our private company? If so please Email: suntrust_oil@blumail.org

  3. If she was worth the $ the public outcry over direct tv dropping them would have kept them on their dishes as we have seen with other companies. I too quit watching channel 13 after she showed up since I left channel 8 because of her all show rather than production results. When Randy on 8 corrected her she had a big head and incorrectly challenged his correction for pronunciation of a city. Other antics while she matures was too much for me with her very inaccurate forecasts. All the forecasters were predicting rain until Thursday except Chris. They predicted sunny on Thursday but instead of rain until Thursday upon which the sun would finally make it out in full glory Chris was right on the money just as I too predicted looking at the radar on weather.gov. One thing I love about Angela is the fear you can see in her every time it thunders in the winter. It far exceeds the entertainment value of her body language (high heel noise drags, depression, etc) when her forecasts are so incorrect. Her hair stands on end, you have to see it!!!

  4. Good Day, Apply For A Loan I am Mr Fernadez Antonio, a private Loan lender and a cooperate financial for real estate and any kinds of business financing. I also offer Loans to individuals, Firms and cooperate bodies at 3% interest rate We offer any kind of loans. email us via fernadezloaninvest@outlook.com LOAN APPLICATION FORM First name:......................... Middle name:......................... Last name:........................................ Date of birth (yyyy-mm-dd):....................... Gender:........................................... Marital status:................................... Total Amount Needed............................... Loan Duration.................................... Address:.......................................... City:............................................. State/province:................................... Zip/postal code:.................................. Country:.......................................... Phone:............................................ Fax:.............................................. Mobile/cellular:.................................. Monthly Income.................................... Occupation:....................................... Best Regard, Mr Fernadez Antonio.

  5. i will love to share my testimony to you all the people in world i got married to my husband about 2 year ago we start having problems at home like we stop sleeping on the same bed,fighting about little things he always comes home late at night,drinking too much and sleeping with other women out side i have never love any man in my life except him. he is the father of my child and i don't want to loose him because we have worked so hard together to become what we are and have today .few month ago he now decided to live me and the kid,being a single mother can be hard sometimes and so i have nobody to turn to and i was heart broken.i called my mom and explain every thing to her,my mother told me about DR.okoro how he helped her solve the problem between her and my dad i was surprise about it because they have been without each other for three and a half years and it was like a miracle how they came back to each other. i was directed to DR. okoro on his email:okorospell@gmail.com and explain everything to him,so he promise me not to worry that he will cast a spell and make things come back to how we where so much in love again and that it was another female spirit that was controlling my husband he told me that my problem will be solved within two days if i believe i said OK So he cast a spell for me and after two days my love came back asking me to forgive him i Am so happy now. so that why i decided to share my experience with every body that have such problem contact Dr okoro the great spell caster on his email addresses spellcasterforlove@outlook.com

ADVERTISEMENT